Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
about
Recent developments in the management of invasive fungal infections in patients with oncohematological diseasesFundament and Prerequisites for the Application of an Antifungal TDM ServiceSerum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyRandomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control studySecondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.Use of antifungal drugs in hematologyInfectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.Invasive aspergillosis in children with acquired immunodeficiencies.Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Pharmacotherapy approaches to antifungal prophylaxis.Voriconazole in clinical practice.Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients.Treatment principles for the management of mold infections.Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries.A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.Acute myeloid leukemia and the infectious diseases consultant.Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial.Invasive aspergillosis before HCT: safe to proceed?Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation.Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.Prophylaxis of invasive fungal diseases in patients with hematologic disordersVoriconazole as secondary antifungal prophylaxis in stem cell transplant recipients.Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis.Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis.Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients (reply).Retrospective assessment of secondary prophylaxis for invasive aspergillosis in neutropenic hematology patients and identification of risk factors for relapse of fungal disease.Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
P2860
Q28077381-568B9F2F-2972-4A57-8F20-71FF15B41D38Q28085352-19AE7EEC-E482-4552-A6B5-51F683076EC6Q34413393-576B1567-DBA8-4CEF-AE00-DF40BD4C522BQ34450423-292F3F94-8DC7-414C-8A64-C96A11592AECQ34532546-CE4EE2F2-BC33-41AD-B4CE-EEFAB2901639Q34543097-CD3E47E9-B35C-4ABD-9B34-D9B9E7D03699Q34756973-D44F1931-2605-4DBC-BBF5-CA9C4E6ECE44Q35659502-5ADD1023-7441-406E-A8C0-D645220AADFBQ35672258-BF020A06-5E61-4DD2-A5E2-D1996B3C836EQ35821259-22657EA4-9A50-4EA2-953D-BF809ABBE327Q36046991-2162BD9B-AFDA-4B12-9B80-1F3D66908CF6Q36364856-4F15FB64-771D-4787-8B05-7EF4F7A40E49Q37150434-A3AA747F-803C-46AD-9603-3D02ACA7F3BDQ37442798-71104E72-9C57-4557-97F8-EAC7FB68D66EQ37636223-4A6BDB4F-F03C-4A69-B04C-017412EDE9C9Q37866827-40FB0667-34F7-4595-BA03-1AC2F4DB970CQ37935599-267C6E7B-002D-4156-A114-E8327F76E38DQ37954958-623AA8E7-1A0B-49ED-9A68-A38BCE94955FQ37993110-C43A4A30-CC2E-4AA2-BAD8-F388F1FD0BA7Q38020238-286E222A-660E-4EB8-9509-25CBDE59E47AQ38061736-8E2FC770-EF2B-4083-9A6D-A6F92EBAC857Q38263489-E9A38271-6130-48EA-BF3D-A5C802468F1FQ38265845-DFD38DBA-E89D-4CE5-BD44-0410C45A2E24Q38388198-809341B7-E129-415B-9296-544101E3E746Q38419657-B7FBE723-5021-4641-8D3E-610A7C2FB1CCQ39196770-D6678EEC-FF31-4C58-9643-3082BD6C7C26Q39479653-FE8D466D-4BB2-4C9F-9136-419539AF146BQ40039262-CC20037A-EC21-440D-A6A5-B02CFF62F4CEQ40303565-83CEC495-31F3-4072-BD7B-DCE1B220F561Q40874890-86324871-D800-48B6-A0B8-630CA335D720Q40886644-08757FEE-A63C-4A88-A218-FCF0CC0FEB52Q41441699-37043632-D4DA-4559-B754-E2AC5B1F476CQ42415929-139A0BE1-7414-467F-8450-06CB8B509B26Q42586750-9B794837-4626-49A8-9F15-732F90B8CF0FQ43975147-9B8DDE70-2D03-49E5-BBD5-5781E7697AA7Q44705704-6D4A56E6-0C03-45C5-8E17-DE6D445F9996Q45757964-EBD33034-FB78-4351-A72F-B76E4813FDB1Q45808812-01793200-661A-42EE-B26D-B1E16AA79E22Q46729472-6A382DC5-4A36-4B24-BC7B-09A1CA2DEFB6Q52746966-10AC7DC2-688A-413E-9436-A6FC04C1EDCE
P2860
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@ast
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@en
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@nl
type
label
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@ast
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@en
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@nl
prefLabel
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@ast
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@en
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@nl
P2093
P2860
P1433
P1476
Voriconazole for secondary pro ...... : results of the VOSIFI study.
@en
P2093
Andrew J Ullmann
Arnaud Pigneux
Catherine Cordonnier
Catherine Faucher
Claus Peter Heussel
Eduardo Olavarria
Effie Liakopoulou
Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation
Johan Maertens
Karin Bilger
P2860
P304
P356
10.3324/HAEMATOL.2009.020073
P577
2010-07-15T00:00:00Z